vs
Side-by-side financial comparison of Limbach Holdings, Inc. (LMB) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Limbach Holdings, Inc. is the larger business by last-quarter revenue ($186.9M vs $103.7M, roughly 1.8× Twist Bioscience Corp). Limbach Holdings, Inc. runs the higher net margin — 6.6% vs -29.4%, a 36.0% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (30.1% vs 16.9%). Limbach Holdings, Inc. produced more free cash flow last quarter ($27.9M vs $-34.8M).
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
LMB vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $186.9M | $103.7M |
| Net Profit | $12.3M | $-30.5M |
| Gross Margin | 25.7% | 52.0% |
| Operating Margin | 9.4% | -31.7% |
| Net Margin | 6.6% | -29.4% |
| Revenue YoY | 30.1% | 16.9% |
| Net Profit YoY | 25.0% | 3.4% |
| EPS (diluted) | $1.01 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $186.9M | $103.7M | ||
| Q3 25 | $184.6M | — | ||
| Q2 25 | $142.2M | — | ||
| Q1 25 | $133.1M | — | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $133.9M | — | ||
| Q2 24 | $122.2M | — | ||
| Q1 24 | $119.0M | — |
| Q4 25 | $12.3M | $-30.5M | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $6.0M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | 25.7% | 52.0% | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 28.0% | — | ||
| Q1 25 | 27.6% | — | ||
| Q4 24 | 30.3% | — | ||
| Q3 24 | 27.0% | — | ||
| Q2 24 | 27.4% | — | ||
| Q1 24 | 26.1% | — |
| Q4 25 | 9.4% | -31.7% | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 5.9% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 6.7% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 6.6% | -29.4% | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.6% | — | ||
| Q2 24 | 4.9% | — | ||
| Q1 24 | 6.4% | — |
| Q4 25 | $1.01 | $-0.50 | ||
| Q3 25 | $0.73 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.85 | — | ||
| Q4 24 | $0.81 | — | ||
| Q3 24 | $0.62 | — | ||
| Q2 24 | $0.50 | — | ||
| Q1 24 | $0.64 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.3M | $197.9M |
| Total DebtLower is stronger | $30.5M | — |
| Stockholders' EquityBook value | $195.7M | $456.1M |
| Total Assets | $381.1M | $638.1M |
| Debt / EquityLower = less leverage | 0.16× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.3M | $197.9M | ||
| Q3 25 | $9.8M | — | ||
| Q2 25 | $38.9M | — | ||
| Q1 25 | $38.1M | — | ||
| Q4 24 | $44.9M | — | ||
| Q3 24 | $51.2M | — | ||
| Q2 24 | $59.5M | — | ||
| Q1 24 | $48.2M | — |
| Q4 25 | $30.5M | — | ||
| Q3 25 | $56.3M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $23.7M | — | ||
| Q4 24 | $23.6M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $19.4M | — |
| Q4 25 | $195.7M | $456.1M | ||
| Q3 25 | $181.6M | — | ||
| Q2 25 | $170.5M | — | ||
| Q1 25 | $161.1M | — | ||
| Q4 24 | $153.5M | — | ||
| Q3 24 | $142.2M | — | ||
| Q2 24 | $133.0M | — | ||
| Q1 24 | $125.5M | — |
| Q4 25 | $381.1M | $638.1M | ||
| Q3 25 | $409.1M | — | ||
| Q2 25 | $343.0M | — | ||
| Q1 25 | $336.4M | — | ||
| Q4 24 | $352.1M | — | ||
| Q3 24 | $324.4M | — | ||
| Q2 24 | $303.9M | — | ||
| Q1 24 | $289.2M | — |
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.1M | $-24.8M |
| Free Cash FlowOCF − Capex | $27.9M | $-34.8M |
| FCF MarginFCF / Revenue | 14.9% | -33.5% |
| Capex IntensityCapex / Revenue | 0.1% | 9.6% |
| Cash ConversionOCF / Net Profit | 2.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.1M | $-24.8M | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $2.0M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $4.9M | — | ||
| Q2 24 | $16.5M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | $27.9M | $-34.8M | ||
| Q3 25 | $12.8M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $11.0K | — | ||
| Q4 24 | $18.0M | — | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $13.2M | — | ||
| Q1 24 | $-6.5M | — |
| Q4 25 | 14.9% | -33.5% | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 12.5% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 10.8% | — | ||
| Q1 24 | -5.5% | — |
| Q4 25 | 0.1% | 9.6% | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | 2.29× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 2.77× | — | ||
| Q1 24 | -0.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
